HWHG(SH:600079) Zhong Guo Zheng Quan Bao - Zhong Zheng Wang·2025-11-22 02:04Core Viewpoint - The company has received approval from the National Medical Products Administration for the registration application of Dexamfetamine Mesylate Capsules, marking a significant step in its product development and potential market expansion [1][2]. Group 1: Product Information - The drug name is Dexamfetamine Mesylate Capsules, classified as a Class 3 chemical drug [1]. - The application is for domestic production and the intended indication is for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients aged 6 and above [2]. - The cumulative R&D investment in this project by the company is approximately 90 million RMB [2]. Group 2: Market Context - Currently, there are no Dexamfetamine Mesylate Capsules available in the domestic market, nor are there any related products approved for import [2]. - The acceptance of the registration application indicates that the product is now entering the review phase, which could enhance the company's product line and market competitiveness if approved [2]. Group 3: Future Outlook - The company will actively promote subsequent related work following the acceptance of the application and will fulfill its information disclosure obligations based on the project's actual progress [2].